Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study

Arthritis and Rheumatology

Volumn 71, Issue 6, 2019, Pages 892-900

  Desai, Rishi J ^a   Pawar, Ajinkya ^a   Weinblatt, Michael E ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VENOUS THROMBOEMBOLISM; AGED; COMPARATIVE STUDY; FACTUAL DATABASE; INCIDENCE; PROPORTIONAL HAZARDS MODEL; VEIN THROMBOSIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; JANUS KINASE INHIBITORS; MALE; MIDDLE AGED; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; PYRIMIDINES; PYRROLES; TUMOR NECROSIS FACTOR INHIBITORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 85059629953     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40798     Document Type: Article

References (13)

1. Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 2016;9:84–93.
2. Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm 2017;23:809–14.
3. US Food and Drug Administration. FDA briefing document: baricitinib janus kinase (JAK) inhibitor for RA. 2018. URL: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM605061.pdf/.
4. Weinblatt M, Taylor PC, Burmester GR, Witt S, Saifan C, Walls C, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: https://acrabstracts.org/abstract/cardiovascular-safety-during-treatment-with-baricitinib-in-rheumatoid-arthritis/.
5. US Food and Drug Administration. Olumiant (baricitinib) drug approval package. URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000TOC.cfm.
6. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–20.
7. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
8. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21:154–62.
9. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–59.
10. Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KF. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology 2017;28:249–57.
11. Mease PJ, Kremer J, Cohen S, Curtis JR, Charles-Schoeman C, Loftus EV, et al. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. Ann Rheum Disease 2018;77 Suppl 2:983.
12. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1600–7.
13. Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf 2018;41:357–61.